Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Cancer Res Treat. 2005 Oct;37(5):257-67. doi: 10.4143/crt.2005.37.5.257. Epub 2005 Oct 31.
Epstein-Bar virus (EBV), a human herpesvirus, establishes a life-long persistent infection in 90 approximately 95% of human adult population worldwide. EBV is the etiologic agent of infectious mononucleosis, and EBV is associated with a variety of human malignancy including lymphoma and gastric carcinoma. Recently, EBV has been classified as group 1 carcinogen by the WHO International Agency for Research on Cancer. Evidence is presented which suggests that failures of the EBV-specific immunity may play a role in the pathogenesis of EBV-associated malignancy. At present, the precise mechanisms by which EBV transforms B lymphocytes have been disclosed. Encouragingly, they have had enough success so far to keep them enthusiastic about novel therapeutic trial in the field of EBV-associated lymphoma. However, information on EBV-associated gastric carcinoma is still at dawn. This article reviews EBV biology, immunological response of EBV infection, unique oncogenic property of EBV, peculiarity of EBV-associated gastric carcinoma, and lastly, EBV-targeted therapy and vaccination.
EB 病毒（EBV），一种人类疱疹病毒，在全球约 90%~95%的成年人群中建立终身持续感染。EBV 是传染性单核细胞增多症的病原体，与多种人类恶性肿瘤有关，包括淋巴瘤和胃癌。最近，世界卫生组织国际癌症研究机构将 EBV 归类为 1 类致癌物。有证据表明，EBV 特异性免疫的失败可能在 EBV 相关恶性肿瘤的发病机制中起作用。目前，已经揭示了 EBV 转化 B 淋巴细胞的确切机制。令人鼓舞的是，到目前为止，它们已经取得了足够的成功，让他们对 EBV 相关淋巴瘤领域的新治疗试验保持热情。然而，关于 EBV 相关胃癌的信息仍处于起步阶段。本文综述了 EBV 的生物学、EBV 感染的免疫反应、EBV 的独特致癌特性、EBV 相关胃癌的特点，以及最后，EBV 靶向治疗和疫苗接种。
